ARTICLE | Company News
Sepracor submits Soltara NDA
March 12, 2001 8:00 AM UTC
SEPR submitted an NDA for its third generation nonsedating antihistamine Soltara norastemizole to treat allergic rhinitis. SEPR developed Soltara with Johnson & Johnson (JNJ), and JNJ is eligible for ...